Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is...

Related Keywords

Pennsylvania ,United States ,Hawaii ,Malvern ,Maria Maccecchini ,Annovis Bio ,Maccecchinim Buntanetap ,Melissa Gaines ,Cheng Fang ,Alzheimer Research Unit ,Hawaii Memory Center Alzheimer Research Unit ,Annovis Bio Inc ,Securities Exchange ,University Hawaii ,Company Annual Report On Form ,Linkedin ,Number Of Responders In Treatment Group ,Twitter ,Research Development ,Mini Mental State Examination ,Disease Assessment Scale Cognitive Subscale ,Disease Cooperative Study Clinician ,Global Impression ,Co Primary Endpoint ,Meyer Alzheimer ,Highly Correlated ,Fold Increase ,Treatment Group ,Memory Disorders ,Research Unit ,Clinical Professor ,Principal Investigator ,Hawaii Memory Center ,Clinical Operations ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Reports ,Novel Translational Inhibitor ,Multiple Neurotoxic Proteins ,Both Alzheimer ,Plasma Phosphorylated Tau ,Alzheimer Disease ,Nat Med ,